Monday, May 8, 2023 Daily Archives

ZETA magnetic mixers cause a stir at Interphex

by

ZETA says its range of hermetically closed bioreactor agitators can help manufacturers dramatically reduce contamination risks. Process engineering and biologics services firm ZETA took to the hall at Interphex in New York last month to demonstrate its range of magnetic agitators used in bioreactors and fermenters. Showing BioProcess Insider the bottom-mounted BMRF, Nicole Zangl, business development manager at ZETA GmbH said the agitator is a completely closed system with Zeta’s plug-in shell solution, which overcomes the contamination risk of conventional…

May 8, 2023

Ginkgo and Boehringer partner to develop therapeutic molecules

by

Boehringer Ingelheim will use Ginkgo Bioworks’ natural product discovery platform to advance the development of novel therapeutics. The specific drug target has not been specified but Ginkgo said the partnership with Boehringer Ingelheim will aim to tackle some of the most complex and “undruggable” targets. Under the terms of the agreement, Ginkgo will receive an upfront research and development (R&D) payment from Boehringer Ingelheim. Additionally, Ginkgo has the potential to gain up to $406 million in R&D, regulatory, and commercial…

May 8, 2023

GSK ready to meet RSV vaccine demand after Arexvy approval

by

Arexvy has become the first FDA approved vaccine to treat respiratory syncytial virus (RSV) and will be produced across GlaxoSmithKline’s European and US manufacturing network. The US Food and Drug Administration (FDA) approved Arexvy last week, for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). “Arexvy contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK’s proprietary AS01E adjuvant,” a spokesperson told BioProcess Insider. “Arexvy will have two vials (one antigen…

May 8, 2023

Merck KGaA to build Asia-Pacific bioprocessing center

by

Germany’s Merck has signed a non-binding Memorandum of Understanding (Mou) with the Korean Ministry of Trade, Industry and Energy (MOTIE) to build a facility in Daejeon City. Merck KGaA said the proposed bioprocessing plant would support commercial manufacturing for biotech and pharmaceutical clients across the Asia-Pacific (APAC) area. Additionally, the firm claimed it plans to work alongside the Daejeon government to support biotech companies that are based in the Daedeok Research complex in Daejeon. Moreover, the collaboration aims to advance the…

May 8, 2023